Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The incidence of false-positive stress tests has been noted in women, especially on hormone replacement therapy. Current literature describes this phenomenon in treadmill and adenosine stress tests. The introduction of regadenoson as a vasodilator agent has been widely adopted owing to its potency and specificity. To our knowledge, false-positive stress test with regadenoson in a postmenopausal woman on estrogen has never been described. Given the higher chronotropic response with regadenoson, we believe that normal perfusion images with a higher heart rate response indicate a good prognosis in such patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413522PMC
http://dx.doi.org/10.1155/2015/653760DOI Listing

Publication Analysis

Top Keywords

postmenopausal woman
8
woman estrogen
8
false-positive stress
8
stress tests
8
significance depression
4
depression postmenopausal
4
estrogen therapy
4
regadenoson
4
therapy regadenoson
4
regadenoson myocardial
4

Similar Publications

Objective: Social media is an increasingly relevant tool for health education, enabling information exchange, promoting autonomy and supporting informed decision-making. This study introduces Menopausando, a predominantly Portuguese-language digital platform designed to support women during menopausal transition and postmenopause.

Method: This cross-sectional study has been carried out in the Gynecology Discipline, São Paulo University, Brazil, since 2019.

View Article and Find Full Text PDF

Unlabelled: The National Osteoporosis Guideline Group (NOGG) has updated the revised UK guideline for the assessment and management of osteoporosis and the prevention of fragility fractures in postmenopausal women, and men age 50 years and older. This guideline is relevant for all healthcare professionals involved in osteoporosis management.

Introduction: The UK National Osteoporosis Guideline Group (NOGG) first produced a guideline on the prevention and treatment of osteoporosis in 2008, with updates in 2013, 2017 and 2021.

View Article and Find Full Text PDF

This case report concerns a male patient in early adolescence who presented to our clinic with several months of abdominal discomfort, irregular bowel habits, tenesmus and a sensation of incomplete evacuation. Previous treatment was through osmotic laxatives. Initial workup of physical examination and endoscopy was inconclusive and did not show any anatomical abnormalities.

View Article and Find Full Text PDF

Importance: There is an unmet need for long-term, safe, effective, and hormone-free treatments for menopausal symptoms, including vasomotor symptoms (VMS) and sleep disturbances.

Objective: To evaluate the 52-week efficacy and safety of elinzanetant, a dual neurokinin-targeted therapy, for treating moderate to severe VMS associated with menopause.

Design, Setting, And Participants: OASIS-3 was a double-blind, placebo-controlled, randomized phase 3 clinical trial that was conducted at 83 sites in North America and Europe from August 27, 2021, to February 12, 2024, and included postmenopausal women aged 40 to 65 years who were seeking treatment for moderate to severe VMS (no requirement for a minimum number of VMS events per week).

View Article and Find Full Text PDF

Background: Iron metabolism may influence breast cancer development; however, links between iron-related biomarkers and breast cancer remain inconclusive. Given differences in iron status by menopausal status, we examined associations of ferritin and other iron biomarkers, with breast cancer incidence, stratified by menopausal status, in a Korean screening cohort.

Methods: This cohort study included 140,747 Korean women screened for breast cancer from 2011-2020.

View Article and Find Full Text PDF